00:33 , Apr 6, 2018 |  BC Innovations  |  Targets & Mechanisms

GI Band-Aid

A trio of...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ADP-ribosylation factor 6 (ARF6); G protein q polypeptide (GNAQ; G-ALPHA-q)

Cancer INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting ARF6 could help treat GNAQ-mutant uveal melanoma. In two human GNAQ-mutant uveal melanoma cell lines, siRNA targeting ARF6 decreased colony-forming units and proliferation compared with...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Sage Therapeutics, National Institutes of Health, Scripps Research Institute, University of Utah neurology news

NIH's Blueprint Neurotherapeutics Network (BPN) granted Sage an award worth up to $10 million to develop a positive allosteric modulator (PAM) of GABA A receptor to treat anxiety and social deficits in patients with fragile...